NCT00433381 2018-09-17Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or GliosarcomaNational Cancer Institute (NCI)Phase 2 Completed123 enrolled 16 charts